Mitral Valve Regurgitation

Current Location

31 Mitral Valve Regurgitation Trials Near You

Power is an online platform that helps thousands of Mitral Valve Regurgitation patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

TMVR for Mitral Valve Regurgitation

Columbus, Ohio
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

1056 Participants Needed

Automated Alerts for Heart Valve Issues

Columbus, Ohio
This multi-center, prospective, cluster-randomized controlled trial will evaluate Tempus Next automated notifications as an intervention to support identification and evaluation of patients possibly indicated for Valve Intervention (VI). This study will evaluate the impact of Tempus Next's automated notifications on: (1) Transcatheter or surgical procedure for AS or MR; and (2) Clinic visit with at least one member of the Multidisciplinary Heart Team (including time to evaluation) for patients with definitive or possible severe AS or MR on echocardiogram. These endpoints will also be examined within and between assigned groups according to race, ethnicity, sex, and geography. The primary question that will be answered: Do automated alerts sent to clinical providers decrease under-treatment of severe aortic stenosis and severe mitral regurgitation? The study will compare the rate of clinical follow-up and aortic valve surgery in a control group (no alerts sent) to a treatment group (alerts sent to an appropriate care provider).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

2626 Participants Needed

Edwards Bioprosthetic Heart Valves for Heart Valve Disease

Columbus, Ohio
The objective of this trial is to confirm that the modifications to tissue processing, valve sterilization and packaging do not raise any new questions of safety and effectiveness in subjects who require replacement of their native or prosthetic aortic or mitral valve.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

777 Participants Needed

Carillon Device for Heart Failure with Mitral Regurgitation

Columbus, Ohio
This trial is testing a device called the Carillon Mitral Contour System, which helps the mitral valve in the heart work better. It targets patients with heart failure and a specific valve problem. The device reshapes the valve to improve its function and reduce symptoms.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

300 Participants Needed

Innovalve Artificial Mitral Valve for Mitral Valve Regurgitation

Columbus, Ohio
This trial is testing a new device called the Innovalve mitral valve replacement system. It is designed for patients who need their mitral valve replaced due to severe damage. The device works by taking over the function of the damaged valve to ensure proper blood flow in the heart.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

65 Participants Needed

Mitral Valve Repair vs. MitraClip Implantation for Mitral Valve Regurgitation

Columbus, Ohio
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

500 Participants Needed

SAPIEN M3 System for Mitral Valve Regurgitation

Columbus, Ohio
This trial will test the safety and effectiveness of the SAPIEN M3 System in patients with severe mitral regurgitation who can't use other treatments. The device helps the heart valve close properly to stop it from leaking. The SAPIEN transcatheter heart valve (THV) has been previously tested and shown to be safe and effective in the pulmonary position.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

900 Participants Needed

CardioMech MVRS for Mitral Valve Regurgitation

Cincinnati, Ohio
This trial is testing a new device called the CardioMech Mitral Valve Repair System (MVRS) to help patients with a leaky heart valve who are at high risk for surgery. The device aims to fix the valve and improve heart function without needing open-heart surgery. The HARPOON Beating Heart Mitral Valve Repair System (MVRS) has shown it can safely and effectively repair the heart valve while the heart is still beating.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

25 Participants Needed

AltaValve for Mitral Valve Regurgitation

Cincinnati, Ohio
Prospective, single-arm, multicenter study to evaluate the safety and performance of the AltaValve for the treatment of moderate to severe or severe mitral valve regurgitation in subjects who are considered high risk for mortality and morbidity from conventional open-heart surgery.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

15 Participants Needed

Foldax TRIA Heart Valve for Mitral Valve Disease

Cincinnati, Ohio
This trial is testing a new artificial heart valve made from special plastic. It is for patients who need a replacement for their faulty mitral valve. The new valve is implanted through surgery to help the heart work better.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

15 Participants Needed

Transcatheter Valve Repair for Mitral Regurgitation

Cincinnati, Ohio
This trial tests a new device called Edwards PASCAL that fixes leaky heart valves without surgery. It is for patients who can't have surgery or haven't improved with other treatments. The device helps the valve close better, stopping blood from leaking backward.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

1247 Participants Needed

Tendyne Transcatheter Mitral Valve System for Mitral Regurgitation

Cincinnati, Ohio
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device. The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) is to evaluate the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System for the treatment of patients with symptomatic, moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral valve disease due to severe mitral annular calcification. This randomized controlled trial will provide the opportunity to evaluate the safety and clinical benefits of the Tendyne Transcatheter Mitral Valve System compared to the MitraClip System in patients with symptomatic, moderate-to-severe or severe mitral regurgitation, within approved MitraClip indications. In addition, the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System will be evaluated in patients with severe mitral annular calcification who are at prohibitive risk for mitral valve surgery. Patients who are not suitable for mitral valve surgery for reasons other than severe mitral annular calcification and are also not suitable for transcatheter repair with MitraClip, will be enrolled in the Non-repairable cohort. Subjects will be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6 months, and annually through 5 years.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

958 Participants Needed

Cephea Valve System for Mitral Regurgitation

Cleveland, Ohio
This trial is testing a new device called the Cephea Mitral Valve System that can fix or replace a damaged heart valve using a thin tube. It aims to help patients with mitral valve disease who need a less invasive treatment than open-heart surgery. The Cephea Mitral Valve System is a new technology developed by Cephea Valve Technologies, aiming to treat severe mitral regurgitation through a less invasive approach.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

50 Participants Needed

Percutaneous vs Surgical Repair for Mitral Valve Regurgitation

Cleveland, Ohio
This is a prospective, multicenter, open-label, randomized trial comparing mitral valve (MV) transcatheter edge-to-edge repair (TEER) to surgical repair (1:1 ratio) in patients with primary, degenerative mitral regurgitation (MR). The trial will be conducted in the U.S., Canada, Germany and the United Kingdom, and is designed as a strategy trial. Thus, all devices legally marketed for TEER of primary degenerative MR in a particular country are eligible to be used in this trial.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:65+

450 Participants Needed

AltaValve System for Mitral Regurgitation

Cleveland, Ohio
This is a prospective, single arm, multicenter, clinical trial designed to evaluate the safety and performance of the AltaValve System for the treatment of mitral regurgitation in a targeted patient population.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

450 Participants Needed

HARPOON™ System for Mitral Valve Regurgitation

Cleveland, Ohio
The objective of the study is to evaluate the safety and effectiveness of the HARPOON™ System in the treatment of patients with severe degenerative mitral regurgitation (DMR).
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:21+

25 Participants Needed

V-Wave Shunt After MitraClip for Heart Failure

Cleveland, Ohio
This is an investigator initiated, prospective study to demonstrate the safety and feasibility of implantation of the V-Wave Interatrial Shunt System (herein called the "V-Wave Shunt" in patients immediately following percutaneous mitral valve repair using the MitraClip system.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

10 Participants Needed

TMVr System for Mitral Valve Regurgitation

Cleveland, Ohio
The study is a prospective, multi-center, single-arm, non-randomized, Early Feasibility Study (EFS) to evaluate the safety and performance of the Half Moon TMVr System in patients with severe, symptomatic mitral regurgitation, who are at high risk for conventional mitral valve surgery.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:21 - 95

30 Participants Needed

Mitral Valve Replacement for Mitral Valve Regurgitation

Cleveland, Ohio
This trial is testing a new device that replaces a damaged heart valve in patients whose mitral valve is not working properly. The new valve helps the heart pump blood more effectively. The Evalve Mitraclip, a device for percutaneous mitral valve repair, is currently being tested.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

123 Participants Needed

Transcatheter Mitral Valve Repair for Mitral Valve Regurgitation

Detroit, Michigan
The purpose of this study is to assess the safety, performance and clinical outcomes of the Edwards PASCAL Transcatheter Mitral Valve Repair (TMVr) System.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

124 Participants Needed

Why Other Patients Applied

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

Tendyne Mitral Valve System for Mitral Regurgitation

Morgantown, West Virginia
The purpose of this study is to evaluate the safety and performance of the Tendyne Mitral Valve System in the treatment of severe mitral regurgitation in patents with functional disability greater than or equal to NYHA Class II, who are not suitable candidates for surgical replacement with otherwise available devices. Follow-up evaluations will be conducted through 5 years post implantation.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

191 Participants Needed

Transcatheter Mitral Valve Replacement for Mitral Valve Regurgitation

Detroit, Michigan
The purpose of this study is to evaluate the safety and initial performance of the Neovasc Tiara Mitral Transcatheter Heart Valve with the Tiara Transapical Delivery System.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

27 Participants Needed

NeoChord DS1000 vs. Surgery for Mitral Valve Regurgitation

Indianapolis, Indiana
The objective of this trial is to assess the safety and effectiveness of the study device in subjects with degenerative mitral valve disease receiving a mitral valve repair without cardiopulmonary bypass (treatment group) when compared to subjects receiving mitral valve repair using standard surgical techniques with cardiopulmonary bypass (control group).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:21+

585 Participants Needed

Transcatheter Mitral Valve Replacement for Mitral Valve Disease

Detroit, Michigan
To assess the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with a failing mitral bioprosthetic valve.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

53 Participants Needed

Transcatheter Mitral Valve Replacement for Mitral Valve Regurgitation

Ann Arbor, Michigan
This trial tests new devices that replace a leaky heart valve without major surgery. It targets high-risk patients who can't undergo traditional surgery. The devices are inserted through a small tube to fix the valve.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

33 Participants Needed

SAPIEN M3 System for Mitral Regurgitation

Detroit, Michigan
This trial will test the safety and effectiveness of the SAPIEN M3 System in patients with severe mitral regurgitation. The device is designed to help the heart valve close properly, preventing blood from flowing backward. The study aims to gather information for future research on this treatment. The SAPIEN M3 System is part of the SAPIEN family of heart valves, which have been used in various applications including aortic and mitral valve replacements.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

74 Participants Needed

Transseptal ViMAC for Mitral Valve Disease

Detroit, Michigan
A prospective multicenter study enrolling high surgical risk patients with severe mitral annular calcification (MAC) and symptomatic mitral valve dysfunction (severe stenosis, ≥ moderate to severe regurgitation, or mixed ≥ moderate stenosis and ≥ regurgitation). There are 2 Arms in this study: 1) "Transseptal (TS) Valve-in-MAC" (ViMAC) Arm, and 2) Natural History of Disease Registry (NHDR) for patients treated with medical treatment only (which includes patients who meet inclusion criteria but can't be treated with transeptal ViMAC due to the presence of anatomical exclusion criteria or other exclusion criteria) and have not had other procedures that may impact outcomes (i.e., alcohol septal ablation or radiofrequency ablation). The study also includes a Registry of Permanently Unassigned" for subjects who undergo preemptive septal ablation procedures (alcohol or radiofrequency) in anticipation of continuing onto ViMAC arm, but are not accepted in the ViMAC Study arm or the patient chooses not to undergo ViMAC procedure.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

185 Participants Needed

TMCA for Mitral Regurgitation

Roanoke, Virginia
This research protocol tests a new technique and devices that we have developed to treat functional mitral valve regurgitation, called transcatheter mitral valve cerclage annuloplasty, otherwise known as "cerclage". Functional mitral valve regurgitation is a condition caused by damaged heart muscle involving the left ventricle which results in mitral valve leakage. This leakage causes heart failure (breathlessness and lack of energy especially when walking or exercising, and hospital admissions for fluid buildup). This is an early feasibility study (EFS) evaluation of special devices, permanently implanted in the heart, to perform mitral cerclage annuloplasty. Mitral cerclage annuloplasty is a catheter procedure performed under X-ray and ultrasound guidance without surgery. The cerclage devices compress the mitral valve like a purse-string. The cerclage device has a special feature that prevents a coronary artery from getting squeezed as part of this purse-string. The protocol has been changed to allow patients who have mitral valve regurgitation despite prior Mitra-Clip treatment, and to allow patients who have symptomatic heart failure with mild mitral regurgitation.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:21 - 99

19 Participants Needed

Transcatheter Edge-to-Edge Repair for Mitral Valve Regurgitation

Toronto, Ontario
Mitral regurgitation may be seen in the setting of cardiogenic shock. Transcatheter edge-to-edge repair (TEER) has been shown to improve outcomes in patients with chronic heart failure. Observational studies suggest improvements in clinical outcomes in patients with mitral regurgitation in the setting of cardiogenic shock; however, there remains a lack of randomized clinical data to support the use of TEER in cardiogenic shock. This study will be a multicenter, open-label, randomized-controlled trial with two study arms: medical therapy and TEER. Patients admitted to the Cardiac Intensive Care Unit (CICU), Cardiac Surgery Intensive Care Unit (CSICU) or Intensive Care Units (ICU) at participating centers will be recruited. The study aims to answer the question: "Does TEER in patients with SCAI stage C or D cardiogenic with concomitant moderate or greater mitral regurgitation improve outcomes as compared to medical therapy?" The study hypothesis is that TEER will lead to an overall improvement in the composite outcome as compared to the medical therapy arm.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

144 Participants Needed

Mobile Health Exercise Regimen for Heart Valve Disease

Nashville, Tennessee
The vast majority of cardiac rehabilitation eligible individuals do not participate in center based cardiac rehabilitation (CBCR). While steps to encourage participation in CBCR are important, many individuals will still not participate for a variety of reasons. This randomized controlled trial is evaluating a home-based cardiac rehabilitation (HBCR) intervention delivered using a custom app and digital tools in patients undergoing transcatheter heart valve interventions (THVIs). After a brief roll-in period, participants not intending to participate in CBCR are randomized to one of three groups: (1) control, (2) HBCR mobile health intervention with hands-off delivery, and (3) HBCR mobile health intervention with interactive delivery. Participants in the intervention groups (hands-off/interactive delivery) will also be randomized to continue the intervention for 12 weeks or 24 weeks. The intervention targets key health behaviors and includes traditional cardiac rehabilitation components. The study will assess the effect of the intervention on clinical events, physical activity, quality of life, and other outcomes. Those who intend to participate in CBCR will be followed in a registry.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

375 Participants Needed

12

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Mitral Valve Regurgitation clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Mitral Valve Regurgitation clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Mitral Valve Regurgitation trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Mitral Valve Regurgitation is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Mitral Valve Regurgitation medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Mitral Valve Regurgitation clinical trials?

Most recently, we added AltaValve System for Mitral Regurgitation, Automated Alerts for Heart Valve Issues and Mobile Health Exercise Regimen for Heart Valve Disease to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

Top Clinical Trials near Santa Monica, CA

Top Tinnitus Clinical Trials near Tampa, FL

Top Clinical Trials near Bloomington, IL

Top Clinical Trials near Bowie, MD

210 Clinical Trials near Danville, IN

Top Clinical Trials near Oklahoma

81 Breast Cancer Trials near Albuquerque, NM

Top Clinical Trials near Boys Town, NE

Top Clinical Trials near Blue Ridge, GA

Top Clinical Trials near Bath, ME

Top HIV/AIDS Clinical Trials

207 Clinical Trials near Chamblee, GA

By Trial

Nilotinib + Radiation for Chordoma

MARVIN Chatbots for Breast Cancer

Chemotherapy + Immunotherapy for Rectal Cancer

GORE EXCLUDER Device for Aortic Aneurysm

Communal Coping Intervention for Type 2 Diabetes

Galcanezumab for Pediatric Migraine

Solifenacin vs Clonidine for Hot Flashes in Breast Cancer Patients

SABR + TTF for Pancreatic Cancer

Dietary Potassium/Sodium Balance for Cardiovascular Health

DPX-Survivac + Hormone/Radiation/Cyclophosphamide for Breast Cancer

Tailored Therapy for Endometrial Cancer

HPV Vaccine + Pembrolizumab for Oropharyngeal Cancer

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial